Overview

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

Bioequivalence of two 12.5 mg empagliflozin/500 mg metformin fixed dose combination tablets compared to the free combination of empagliflozin 25 mg and metformin 1000 mg in healthy male and female volunteers under fed conditions

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Empagliflozin
Metformin